The global Parenteral Nutrition market size was estimated at USD 6.7 billion in 2021 and is expected to surpass around USD 10.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.4% during the forecast period 2022 to 2030.
Key Takeaways:
Development of technically advanced parenteral nutrition products with barcode assistance, growing preference for parenteral nutrition over enteral nutrition in patients with COVID-19, shorter hospital stays, along with the reduced risk of infection are factors expected to boost the product demand, thereby driving the market. According to the ASPEN20 Virtual Conference, providing appropriate nutrition to adults with COVID-19 remains a priority for optimizing outcomes. This includes overcoming various challenges amid the pandemic, such as a shortage of parenteral nutrition products due to a disrupted supply chain.
Moreover, the increasing prevalence of chronic conditions, majorly cancer & malnutrition, and the rapidly growing geriatric population and natality incidence are key high impact-rendering drivers for market growth. Increasing natality is expected to be another major market driver. Various benefits associated with parenteral nutrition cover easy usage, stimulating stomach blood flow, providing efficient nutrients, and preserving muscle catabolism. An increase in awareness about these benefits is likely to help boost the product demand. For instance, educational campaigns pertaining to health awareness particularly emphasizing nutrition and various initiatives have been undertaken to promote health & social care.
PN can be given to children and infants suffering from a disease or medical condition, thereby requiring special nutritional management. Specialized Nutrition Europe (SNE) estimated that nearly 300,000 EU children are anticipated to require medical nutrition for their special medical needs in early life stages, which supports growth and development. The study further reveals that about 40% of the hospitalized adult patients are malnourished and need medical nutrition to manage the disease-related malnutrition condition, thereby reducing the duration of hospital stay. Parenteral nutrition further lowers the infection risk and underdevelopment, thereby promoting its adoption worldwide.
Most of the premature babies suffer from low weight and undeveloped immunity, which puts them at risk. In addition, individuals and healthcare authorities are extensively focusing on limiting mortality due to early birth, thereby driving the use of parenteral lipid emulsions. In 2016, the premature birth rate in the U.S. was about 9.6% and national authorities are working toward reducing it to 8.1%, according to the National Center for Healthcare Statistics. Moreover, a rise in the number of hospitalizations for COVID-19 patients during this pandemic further boosted the product adoption in various hospitals, clinics, and Ambulatory Surgical Centers (ASCs).
Report Scope of the Parenteral Nutrition Market
Report Coverage |
Details |
Market Size |
US$ 10.9 Billion by 2030 |
Growth Rate |
CAGR of 6.4% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Nutrient type and Region, |
Companies Mentioned |
Baxter; Grifols, S.A.; Allergan; Otsuka Pharmaceutical Factory, Inc.; Actavis Inc.; B. Braun Melsungen AG; Fresenius Kabi AG; Vifor Pharma; Sichuan Kelun Pharmaceutical Co., Ltd.; Pfizer Inc. (Hospira Inc.) |
Nutrient Type Insights
In 2021, the single-dose amino acid solution segment accounted for the largest market share of more than 30.5%. This can be attributed to the increased usage of amino acid solutions, which can be related to an increase in the influx of regulatory-approved solutions. Moreover, newly available amino acid solutions possess fewer side effects, thereby enhancing patient benefits. Aminosyn (by Hospira, Inc.) and Nirmin (by Nirlife Pharma) are a few of the single-dose amino acid solutions available in the market. Formulations of mixed amino acids provide essential and nonessential amino acids; hence, the standard component acts as comprehensive parenteral nutrition for the overall biological functioning.
Parenteral lipid emulsion segment is anticipated to register the fastest growth during the forecast period. In addition, the parenteral lipid emulsions segment is projected to witness the fastest growth rate over the forecast period. The development of hybrid parenteral lipid emulsions using mixed lipid emulsions of fish oil and olive oil, growing adoption of parenteral nutrition over enteral nutrition in COVID-19 patients, shorter hospital stays, and reduced risk of infection are factors expected to boost the demand for parenteral lipid emulsions, thereby driving the segment growth.
Regional Insights
North America accounted for the largest market share of more than 41% in 2021. Key factors responsible for its highest market share include high research expenditure by private entities & government agencies in the healthcare sector; technologically advanced medical devices; and collaborations among the medical device industry, regulatory authorities, universities, and others. In addition, the growing prevalence of various chronic diseases, such as cancer and malnutrition, and the presence of advanced healthcare facilities, favorable reimbursement policies & regulations in the region have led to a high hospital admission rate, which supported the high product demand.
Asia Pacific is anticipated to register the fastest CAGR during the forecast period. The growing prevalence of chronic diseases due to unhealthy eating habits and rising demand for cost-effective treatment of care are some of the factors expected to drive the Asia Pacific regional market growth. Moreover, increasing population, coupled with poverty, and low awareness about nutrition in the region are leading to malnutrition, which is one of the key factors boosting the product demand.
Key Companies & Market Share Insights
Continuous investments from key operating players for the development of advanced PN solutions have led them to gain a competitive edge in the market, thereby driving the market growth. For instance, in January 2020, Fresenius Kabi completed its clinical trial for SmofKabiven. SmofKabiven is their new launch in the range of lipid emulsions. It is made of multiple oils (fish, soybean, & olive oils, and medium-chain triglycerides) along with a separate chamber for amino acids, glucose, and lipids. In addition, companies are actively involved in improving their current product portfolio to sustain their position in the market. New drug development by companies and their entry in the untapped markets to expand their reach are also expected to boost the market growth. Some of the key players operating in the global parenteral nutrition market are:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Parenteral Nutrition market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Parenteral Nutrition Market Study:
Chapter 1 Methodology and Scope
1.1 Research Process
1.2 Information Procurement
1.2.1 Purchased database:
1.2.1.1 Nova one advisor’s internal database
1.2.2 Market Formulation & Validation
1.3 Research Methodology
1.4 Research Scope and Assumptions
1.5 Research Methodology
1.5.1 Region Market: Cagr Calculation
1.5.2 Region Based Segment Share Calculation
1.6 List To Data Nutrient Type
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
2.4 Parenteral Nutrition Market Snapshot
Chapter 3 Parenteral Nutrition Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 User Perspective Analysis
3.3.1 Consumer Behavior Analysis
3.3.2 Market Influencer Analysis
3.4 Regulatory Framework
3.4.1 Reimbursement Framework
3.4.2 Standards & Compliances
3.5 Market Variable Analysis
3.5.1 Market Driver Analysis
3.5.2 Market Restraint Analysis
3.5.2 Industry Challenges
3.6 Parenteral Nutrition Market: Analysis Tools
3.6.1 Porter’s Five Forces Analysis
3.6.2 Pestel Analysis
3.6.3 Major Deals & Strategic Alliances Analysis
3.6.4 Market Entry Strategies
3.7 Impact of COVID-19 on Parenteral Nutrition Market.
Chapter 4 Parenteral Nutrition Market: Nutrient Type Estimates & Trend Analysis
4.1 Segment Dashboard
4.2 Parenteral Nutrition Market: Nutrient Type Movement Analysis, USD Million, 2021 & 2030
4.2.1 Carbohydrates
4.2.1.1 Carbohydrates Market Estimates And Forecasts, 2016 – 2030 (USD Million)
4.2.2 Parenteral Lipd Emulsion
4.2.2.1 Parenteral Lipd Emulsion Market Estimates And Forecasts, 2016 – 2030 (USD Million)
4.2.3 Single Dose Amino Acid Solution
4.2.3.1 Single Dose Amino Acid Solution Market Estimates And Forecasts, 2016 – 2030 (USD Million)
4.2.4 Trace Elements
4.2.4.1 Trace Elements Market Estimates And Forecasts, 2016 – 2030 (USD Million)
4.2.5 Vitamins & Minerals
4.2.5.1 Vitamins & Minerals Market Estimates And Forecasts, 2016 – 2030 (USD Million)
Chapter 5 Parenteral Nutrition Market: Competitive Analysis
5.1 Company Market Position Analysis
5.2 Strategic Framework
Chapter 6 Parenteral Nutrition Market: Regional Estimates & Trend Analysis: By Nutrient Type
6.1 Regional Market Snapshot
6.2 Parenteral Nutrition Market: Regional Movement Analysis, USD Million, 2021 & 2030 (USD Million)
6.3 North America
6.3.1 North America Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.3.2 U.S.
6.3.2.1 U.S. Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.3.3 Canada
6.3.3.1 Canada Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.4 Europe
6.4.1 Europe Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.4.2 Germany
6.4.2.1 Germany parenteral nutrition market estimates and forecasts, 2016 - 2030 (USD Million)
6.4.3 U.K.
6.4.3.1 U.K. parenteral nutrition market estimates and forecasts, 2016 - 2030 (USD Million)
6.4.4 Italy
6.4.4.1 Italy Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.4.5 Spain
6.4.5.1 Spain Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.4.6 France
6.4.6.1 France Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.5 Asia Pacific
6.5.1 Asia Pacific Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.5.2 China
6.5.2.1 China Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.5.3 India
6.5.3.1 India Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.5.4 Japan
6.5.4.1 Japan Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.5.5 Thailand
6.5.5.1 Thailand Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.6.6 South Korea
6.6.6.1 South Korea parenteral nutrition market estimates and forecasts, 2016 - 2030 (USD Million)
6.7 Latin America
6.7.1 Latin America parenteral nutrition market estimates and forecasts, 2016 - 2030 (USD Million)
6.7.2 Brazil
6.7.2.1 Brazil Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.7.3 Mexico
6.7.3.1 Mexico Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.7.4 Argentina
6.7.4.1 Uruguay Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.7.5 Colombia
6.7.5.1 Colombia Parenteral Nutrition Market Estimates And Forecasts, 2016 - 2030 (USD Million)
6.8 MEA
6.8.1 MEA parenteral nutrition market estimates and forecastss, 2016 - 2030 (USD Million)
6.8.2 SOUTH AFRICA
6.8.2.1 South Africa parenteral nutrition market estimates and forecasts, 2016 - 2030 (USD Million)
6.8.3 Saudi Arabia
6.8.3.1 Saudi Arabia parenteral nutrition market estimates and forecasts, 2016 - 2030 (USD Million)
6.8.4 UAE
6.8.4.1 UAE parenteral nutrition market estimates and forecasts, 2016 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Company Profiles
7.1.1 B. BRAUN MELSUNGEN AG
7.1.1.1 Company Overview
7.1.1.2 Financial Performance
7.1.1.3 Product Benchmarking
7.1.1.4 Strategic initiatives
7.1.2 FRESENIUS KABI AG
7.1.2.1 Company Overview
7.1.2.2 Financial Performance
7.1.2.3 Product Benchmarking
7.1.2.4 Strategic Initiatives
7.1.3 ALLERGAN
7.1.3.1 Company Overview
7.1.3.2 Financial Performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 GRIFOLS, S.A.
7.1.4.1 Company Overview
7.1.4.2 Financial Performance
7.1.4.3 Product Benchmarking
7.1.4.4 Strategic Initiatives
7.1.5 PFIZER, INC.(HOSPIRA)
7.1.5.1 Company Overview
7.1.5.2 Financial Performance
7.1.5.3 Product Benchmarking
7.1.5.4 Strategic Initiaves
7.1.6 OTSUKA PHARMACEUTICAL FACTORY, INC.
7.1.6.1 Company Overview
7.1.6.2 Financial Performance
7.1.6.3 Product Benchmarking
7.1.6.4 Strategic Initiaves
7.1.7 BAXTER
7.1.7.1 Company Overview
7.1.7.2 Financial Performance
7.1.7.3 Product Benchmarking
7.1.7.4 Strategic Initiatives
7.1.8 ACULIFE (NIRLIFE)
7.1.8.1 Company Overview
7.1.8.2 Financial Performance
7.1.8.3 Product Benchmarking
7.1.8.4 Strategic Initiatives
7.1.9 SICHUAN KELUN PHARMACEUTICAL CO., LTD
7.1.9.1 Company Overview
7.1.9.2 Financial Performance
7.1.9.3 Product Benchmarking
7.1.9.4 Strategic Initiatives
7.1.10 VIFOR PHARMA
7.1.10.1 Company Overview
7.1.10.2 Financial Performance
7.1.10.3 Product Benchmarking
7.1.10.4 Strategic Initiatives